Caricamento...
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma
Pembrolizumab is an effective therapy in patients with metastatic melanoma. However, not all patients derive benefit. It is postulated that an increase in regulatory T cells in melanoma patients can impair the response to immunotherapies. Continuous low dose temozolomide has shown to cause immunomod...
Salvato in:
| Pubblicato in: | Melanoma Res |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717692/ https://ncbi.nlm.nih.gov/pubmed/30829928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000592 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|